The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
-
BUSINESS Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
-
COMMENTARY There’s Room for Growth in Biosimilar Space, but Who Will Grab It?
August 3, 2018
-
BUSINESS AstraZeneca’s AI Translation System Could Bring Huge Impact If Materialized: Japan R&D Chief
August 2, 2018
-
BUSINESS Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology
August 1, 2018
-
BUSINESS AI in Pharma - 2: Daiichi Sankyo Looks to Set Competitors Apart with Efficient Call Center
August 1, 2018
-
REGULATORY Inappropriate Drug Promotion at Clinics Involves Encouragement of Off-Label Use in Most Cases: Study
July 31, 2018
-
BUSINESS AI in Pharma - 1: Companies Going Digital in Sales Support but Still Embrace Rep Experience
July 30, 2018
-
BUSINESS Chugai Sees Solid Uptake for Tecentriq, Hemlibra but CEO Frets Pricing Stability
July 27, 2018
-
BUSINESS (Update) Eisai/Biogen Alzheimer’s Drug BAN2401 Slows Cognitive Decline by 30%
July 26, 2018
-
REGULATORY AMED Launches Study on Evaluating the Quality and Safety of Nucleic Acid Medicines to Promote Their Development
July 25, 2018
-
ACADEMIA Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
-
BUSINESS Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
July 23, 2018
-
BUSINESS Maruho to Increase Information Supply to Non-Dermatologists Using Digital Technology
July 23, 2018
-
BUSINESS Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard
July 20, 2018
-
REGULATORY Lawmakers Question Rationale for PMD Law Amendment as LDP Launches Debate
July 19, 2018
-
ACADEMIA Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
-
BUSINESS Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo
July 17, 2018
-
TRENDS As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
July 13, 2018
-
BUSINESS Otsuka Ventures into Antibody Space with Visterra Buyout
July 12, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…